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Background/Aims: Proton pump inhibitors (PPIs) and 
histamine-2 receptor antagonists (H2RAs) are commonly 
prescribed for stress ulcer prophylaxis (SUP) in critically ill 
patients. Several studies have suggested that the use of PPIs 
is a potential risk factor for Clostridium difficile infection (CDI). 
We compared the incidences of CDI in the PPI group and 
H2RA group for SUP in critically ill patients. Methods: From 
August 2005 to July 2012, the incidences of CDI were retro-
spectively analyzed in patients who were admitted directly 
to intensive care units and stayed for more than 3 days. 
SUP-related CDI was defined as a CDI diagnosed during the 
SUP period. Patient clinical data were analyzed to identify 
potential risk factors for SUP-related CDI. Results: Of the 
1,005 patients enrolled (444 patients received PPI and 561 
received H2RA), 38 (3.8%) were diagnosed with SUP-related 
CDI. The incidence of SUP-related CDI was considerably high-
er in patients who received PPI than in those who received 
H2RA (6.7% vs 1.8%). PPI use for SUP (odds ratio [OR], 3.3; 
confidence interval [CI], 1.5 to 7.1; p=0.003) and diabetes 
mellitus (OR, 2.3; CI, 1.2 to 4.7; p=0.019) were independent 
risk factors for SUP-related CDI. Conclusions: PPI therapy is 
associated with a higher risk of SUP-related CDI than H2RA 
therapy in critically ill patients. (Gut Liver 2016;10:581-586)
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INTRODUCTION
Clostridium difficile infection (CDI) is the most common cause 
of hospital-acquired infectious diarrhea and can be an impor-
tant cause of morbidity and death. CDI can worsen clinical 
signs at a crucial time in critically ill patients. The development 
of CDI in critically ill patients is associated with high mortality 
and excessive lengths of stay in intensive care units (ICUs) and 
hospitals.1,2
The efficacy of stress ulcer prophylaxis (SUP) in critically ill 
patients is well established, and gastric acid suppressants are 
commonly prescribed in ICUs.3 In a French multicenter study, 
32% of ICU patients received SUP.4 Consequently, upper gastro-
intestinal (UGI) bleeding from stress-related mucosal injury has 
declined half over the past two decades.5 Proton pump inhibitors 
(PPIs) and histamine-2 receptor antagonists (H2RAs) are gener-
ally prescribed for this purpose. It is unclear which drug is more 
effective in preventing UGI bleeding.6,7 Nevertheless, the use 
of PPIs as drug of first choice for SUP has gradually increased 
from 3% in 1998 to 23% in 2002.8
Recent studies have suggest that PPIs are associated with 
the development of CDI in the community and in hospital.9-11 
A meta-analysis of 42 observational studies involving 313,000 
participants demonstrated that PPI treatment was associated 
with the occurrence and recurrence of CDI, whereas H2RA treat-
ment was less harmful.12
Although gastric acid suppressants for SUP in critically ill 
patients have been widely used, there are few studies to analyze 
increasing incidence of CDI in these patients.13-15 Only a handful 
of studies have examined the risk of CDI in ICUs and general 
wards.12,16,17 This study was performed retrospectively to exam-
ine whether PPIs used for SUP in an ICU are associated with a 
higher incidence of CDI than H2RAs. We hypothesized that the 
use of PPIs in critically ill patients is associated with a higher 
incidence of CDI than the use of H2RAs.
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MATERIALS AND METHODS 
1. Patients and study design
We conducted a retrospective study of patients aged at least 
18 years who were admitted directly to an ICU between August 
2005 and July 2012 and remained there for more than 3 days. 
Hanyang University Guri Hospital is an urban, academic facility 
with 600 licensed beds, and it houses 30 ICU beds without sepa-
rate medical or surgical units. In order to compare the effects 
of the SUP agents on the development of CDI, we excluded pa-
tients with crossover use of the SUP agents, with no use of SUP 
agents, and with use of SUP agents for less than 3 days. Of the 
remaining patients—who received a single type of gastric acid 
suppressant—those with any of the following were subsequently 
excluded: (1) prior use of antibiotics within 2 months of admis-
sion; (2) prior use of a PPI or H2RA within 1 month of admis-
sion; (3) a diagnosis of CDI on admission; and (4) transfer to the 
ICU from another hospital during treatment (Fig. 1).
The study was approved by the Institutional Review Board of 
Hanyang University Guri Hospital.
2. Definitions and data collection
SUP was defined if a patient in the ICU received a gastric acid 
suppressant for at least 3 days. CDI was defined as new onset of 
two or more unformed bowel movements per day more than 48 
hours after admission and if Clostridium difficile toxin was con-
firmed by the Premier® toxins A and B enzyme immune assay 
(Meridian Bioscience Inc., Cincinnati, OH, USA) or stool poly-
merase chain reaction. If CDI developed during SUP or within 3 
days after SUP, we regarded it as a SUP-related CDI.
Patient’s demographic and clinical data were collected ret-
rospectively from electronic medical records. All clinical data 
were collected from admission to 3 days after SUP, which was 
taken to be the period of gastric acid suppression, or to the time 
of CDI development. Clinical data included age, sex, body mass 
index, diagnosis on admission, comorbid illness (hypertension, 
coronary artery disease [CAD], diabetes mellitus [DM], chronic 
respiratory disease, immune suppression, end-stage renal dis-
ease [ESRD], malignancy, and cirrhosis), and use of antibiotics 
and immunosuppressive agents, mechanical ventilation and 
mortality. Acute physiology and chronic health evaluation 
(APACHE) II scores were calculated for each patient to evaluate 
severity of illness on admission based on vital signs, laboratory 
results and the Glasgow coma scale. Since antibiotic treatment 
is a well-established risk factor for CDI, we characterized anti-
biotic treatment in terms of number of antibiotics (none, one, 
two, and more than two) and history of high risk antibiotic use 
(cephalosporin, penicillin, vancomycin, fluoroquinolone, and 
carbapenem).
3. Statistical analysis
Univariate analysis was used to screen for potential risk 
factors that affect the development of CDI during gastric acid 
suppression using the chi-square test for categorical variables 
or Student t-test, depending on the distribution of the variable. 
We judged that a factor was a potential risk factors when the 
p-value was <0.05. Logistic regression analysis was used for 
multivariate analysis, and to estimate odds ratios and their 95% 
confidence intervals. An overall p-value <0.05 was required for 
statistical significance. Statistical analyses were performed with 
SPSS version 12.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
1. Baseline characteristics and clinical data at admission
A total of 2,339 patients who were above the age of 18 years, 
were admitted directly to the ICU, and stayed longer than 3 
days were identified during the study period. Of these, 1,087 
were excluded because they received no SUP treatment or there 
was crossover use of gastric acid suppressive agents. Of the re-
maining 1,252 patients treated for SUP with a single agent for 
at least 3 days, 247 patients were subsequently excluded; 95 for 
prior use of gastric acid suppressants, 40 for prior use of antibi-
otics, 109 for transfer from another hospital and 3 for recurrent 
CDI (Fig. 1). Finally 1,005 patients were enrolled and their base-
line characteristics were shown in Table 1. 
The median age of the enrolled patients was 60.8 years. The 
most frequent diagnosis at admission was cerebral hemor-
rhage (39.3%), followed by heart problems (18.5%). The mean 
APACHE II score was 20.2. Mean duration of SUP treatment 
was 13.2 days. A PPI for SUP was prescribed for 444 patients, 
while the remaining 561 patients were prescribed an H2RA. 
Among a total of 1,005 enrolled patients, 834 patients (83.0%) 
received antibiotics treatment during the SUP period or before 
the diagnosis of CDI. 
The characteristics of PPI group and H2RA group were com-
pared in Table 2. The mean age of the PPI group was signifi-
Fig. 1. Flow diagram of the study. 
ICU, intensive care units; PPI, proton pump inhibitor; H2RA, hista-
mine-2 receptor antagonists; CDI, Clostridium difficile infection.
1,005 Patients with directly admitted
to ICU with stress ulcer prophylaxis
1,334 Excluded
396 Crossover use
691 No stress ulcer prophylaxis in ICU
95 Prior PPI or H2RA use
40 Prior antibiotics use
109 Transferral from other hospital
3 Recurrent CDI
2,339 Patients with directly admitted
to ICU and stayed more than 3 days
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cantly higher than that of the H2RA group. The comorbidities 
(CAD, DM, heart failure, ESRD, and liver cirrhosis) and total 
days of SUP were significantly higher in the PPI group than in 
the H2RA group. On the contrary, use of steroid, total days of 
ICU stay, treatment of mechanical ventilator, and mortality rate 
were significantly higher in the H2RA group than in the PPI 
group.
2. Incidence and risk factors for SUP-related CDI
Fifty-two patients (5.2%) were diagnosed as a CDI during 
their hospital stay and 38 (3.8%) were diagnosed as a CDI dur-
ing the SUP period. These 38 patients were regarded as a SUP-
related CDI. The incidence of SUP-related CDI in the PPI group 
(6.3%, 28/444) was significantly higher than in the H2RA group 
(1.8%, 10/561). The clinical characteristics between the “SUP-
Table 1. Baseline Characteristics of Patients
Characteristic Value
Age, yr 60.8±16.1
Sex
    Male 613 (71.0)
    Female 392 (39.0)
APACHE II score 20.2±6.8
Reason of admission
    Heart problem 186 (18.5)
    Renal problem 27 (2.7)
    Respiratory problem 48 (4.8)
    Gastrointestinal problem 81 (8.1)
    Intracrainal hemorrhage 395 (39.3)
    Cerebral infarction 68 (6.8)
    Sepsis 41 (4.1)
    Others 159 (15.8)
Comorbidity
    Hypertension 437 (43.5)
    Coronary artery disease 152 (15.1)
    Diabetes mellitus 262 (26.1)
    Chronic respiratory disease 55 (5.5)
    Heart failure 118 (11.7)
    Immune suppression 8 (0.8)
    End stage renal disease 58 (5.8)
    Malignancy 40 (4.0)
    Liver cirrhosis 70 (7.0)
Total days of ICU stay 17.2±28.9
Total days of hospital stay 39.5±60.1
Mortality 271 (27.0)
Stress ulcer prophylaxis
    PPI 444 (44.2)
    H2RA 561 (55.8)
Total days of SUP 13.2±13.4
No. of antibiotics
    0 171 (17.0)
    1 203 (20.2)
    2 390 (38.8)
    ≥3 241 (24.0)
Types of antibiotics
    Cephalosporin 710 (70.6)
    Fluoroquinolone 189 (18.8)
    Carbapenem 80 (8.0) 
    Penicillin 182 (18.1) 
    Vancomycin 77 (7.7)
Use of steroid (more than 5 day) 385 (38.3)
Mechanical ventilator (more than 48 hr) 470 (46.8)
Diagnosis of CDI during hospital stay 52 (5.2)
Diagnosis of SUP related CDI 38 (3.8)
Data are presented as number (%) or mean±SD.
APACHE, acute physiology and chronic health evaluation; ICU, in-
tensive care units; PPI, proton pump inhibitor; H2RA, histamine-2 
receptor antagonists; SUP, stress ulcer prophylaxis; CDI, Clostridium 
difficile infection.
Table 2. Comparison of the PPI Group and H2RA Group
Patient demographics
H2RA group 
(n=561)
PPI group 
(n=444)
p-value
Female sex 228 (40.6) 164 (36.9) 0.13
Age, yr 58.7±16.1 63.5±15.7 <0.001
Total days of SUP 11.9±12.8 14.8±13.9 0.001
Total days of ICU stay 21.5±35.8 11.9±14.7 <0.001
Use of antibiotics 491 (87.5) 343 (77.3) <0.001
No. of antibiotics 0.02
    0 70 (12.5) 101 (22.7)
    1 71 (12.7) 132 (29.7)
    2 292 (52.0)  98 (22.1)
    ≥3 128 (22.8) 113 (25.5)
Comorbidity
    Hypertension 250 (44.6)  187 (42.1) 0.24
    Coronary artery disease 34 (6.1)  118 (26.6) <0.001
    Diabetes mellitus 108 (19.3)  154 (34.7) <0.001
    Chronic respiratory disease 24 (4.3)  31 (7.0) 0.04
    Heart failure 30 (5.3)  88 (19.8) <0.001
    End stage renal disease 11 (2.0)  47 (10.6) <0.001
    Malignancy 19 (3.4)  21 (4.7) 0.18
    Liver cirrhosis  6 (1.1)  64 (14.4) <0.001
Body mass index* 23.1±3.6 22.8±3.6 0.39
Use of steroid (more than 5 day)  350 (62.4)  35 (9.1) <0.001
Mechanical ventilator 
  (more than 48 hr) 
 276 (49.2)  194 (43.5) 0.05
APACHE II score 20.6±6.2 19.8±7.5 0.07
Mortality  172 (30.7)  99 (22.3) 0.002
Data are presented as number (%) or mean±SD.
PPI, proton pump inhibitor; H2RA, histamine-2 receptor antagonists; 
SUP, stress ulcer prophylaxis; ICU, intensive care units; APACHE, acute 
physiology and chronic health evaluation.
*These data were calculated from the 698 patients out of a total of 
1,005 patients.
584  Gut and Liver, Vol. 10, No. 4, July 2016
related CDI group” and the “no CDI group” were compared 
in Table 3. In univariate analysis, PPI use for SUP, number of 
antibiotics, total days of ICU stay, CAD, DM, and ESRD were 
significantly associated with the development of CDI during the 
gastric acid suppression period. Use of carbapenem and van-
comycin among the antibiotics were risk factors in univariate 
analysis. In multivariate analysis, PPI treatment and DM were 
independent risk factors for SUP-related CDI (Table 4).
In addition, we reviewed the clinical outcomes of SUP-related 
CDI between the PPI and the H2RA group. Due to the limita-
tion of retrospective study, we were able to analyze 27 patients 
out of a total of 38 SUP-related CDI patients. In the PPI group, 
we could analyze the clinical outcomes of 17 patients among 
28 patients with SUP-related CDI. Among them, there was no 
recurrence and one patient died of CDI-unrelated cause. On the 
other hand, in the H2RA group, SUP-related CDI was developed 
in 10 patients. Among them, CDI was recurred in one patients, 
and another one patient died of CDI-unrelated cause. There was 
no significant difference in the clinical outcomes between the 
PPI and the H2RA group, although sample size was too small. 
DISCUSSION
Our study evaluated the incidence of CDI in critically ill pa-
tients receiving a PPI versus H2RA for SUP. In this retrospective 
study, we found that the risk of SUP-related CDI was three-
times higher in the PPI treatment group than in the H2RA treat-
ment group. The overall incidence of CDI during the gastric acid 
suppression period in critically ill patients was 3.8% (38/1,005), 
which is higher than those (0.5% to 1.2%) of previous re-
ports.12,17 This discrepancy may be associated with more severe 
illness in our study population relative to those of previous 
Table 3. Comparison of the SUP-Related CDI Group and Non-CDI 
Group
Patient demographics
SUP-related 
CDI (n=38)
No CDI 
(n=953)
p-value
Stress ulcer prophylaxis
    PPI 28 (73.7) 416 (43.7) <0.001
    H2RA 10 (26.3) 527 (55.3) <0.001
Female sex 16 (42.1) 367 (38.5) 0.74
Age, yr 64.8±14.1 60.7±16.1 0.09
Total days of SUP 15.2±11.9 13.1±13.4 0.35
Total days of ICU stay 28.2±29.2 16.8±28.8 0.02
Use of antibiotics 35 (92.1) 799 (83.8) 0.09
No. of antibiotics 0.02
    0 3 (7.9) 154 (16.2)
    1 15 (39.5) 188 (19.7)
    2 10 (26.3) 380 (39.9)
    ≥3 10 (26.3) 231 (24.2)
Types of antibiotics
    Cephalosporin 25 (65.8) 594 (62.3) 0.86
    Fluoroquinolone 10 (26.3) 178 (18.7) 0.29
    Carbapenem 7 (18.4) 73 (7.7) 0.03
    Penicillin 9 (23.7) 170 (17.8) 0.39
    Vancomycin 7 (18.4) 69 (7.2) 0.02
Comorbidity
    Hypertension 21 (55.3) 399 (41.9) 0.13
    Coronary artery disease 0 152 (15.9) 0.002
    Diabetes mellitus 19 (50.0) 238 (25.0) 0.002
    Chronic respiratory disease 0 55 (5.8) 0.27
    Heart failure 4 (10.5) 113 (11.9) 0.52
    Immune suppression 0 8 (0.8) 0.72
    End stage renal disease 8 (21.1) 49 (5.1) 0.001
    Malignancy 0 40 (4.2) 0.40
    Liver cirrhosis 3 (7.9) 67 (7.0) 0.75
Body mass index* 23.4±3.5 22.9±3.6 0.47
Use of steroid 
  (more than 5 day)
9 (23.7) 357 (37.5) 0.09 
Mechanical ventilator 
  (more than 48 hr)
22 (57.9) 448 (47.0) 0.19 
APACHE II score 21.0±6.7 20.1±6.8 0.90
Mortality 5 (13.2) 261 (27.4) 0.61
Data are presented as number (%) or mean±SD.
SUP, stress ulcer prophylaxis; CDI, Clostridium difficile infection; PPI, 
proton pump inhibitor; H2RA, histamine-2 receptor antagonists; ICU, 
intensive care units; APACHE, acute physiology and chronic health 
evaluation.
*These data were calculated from the 698 patients out of a total of 
1,005 patients.
Table 4. Risk Factors for Developing SUP-Related CDI in Multivariate 
Analysis
Variable OR 95% CI p-value
Age 1.0 0.9–1.0 0.26
Total days of SUP 1.0 0.9–1.0 0.42
Total days of ICU stay 1.0 0.9–1.1 0.06
PPI for SUP 3.3 1.5–7.1 0.003
Use of antibiotics 2.3 0.9–5.8 0.07
Coronary artery disease 0.0 0.00 0.99
Diabetes mellitus 2.3 1.2–4.7 0.019
Heart failure 0.7 0.2–2.1 0.56
End stage renal disease 2.1 0.8–5.3 0.12
Liver cirrhosis 0.9 0.3–3.0 0.83
Use of steroid 0.5 0.2–1.0 0.06
SUP, stress ulcer prophylaxis; CDI, Clostridium difficile infection; OR, 
odds ratio; CI, confidence interval; ICU, intensive care units; PPI, pro-
ton pump inhibitor.
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studies; the patients enrolled in previous studies were admitted 
to both ICUs and general wards.12,16-18 In addition, considering 
that the incidence of general health care-associated CDI was 12 
per 1,000 patient days,19,20 our data confirmed that ICU patients 
are more vulnerable to CDI than patients on a general ward. 
Since the occurrence of CDI in critically ill patients is associated 
with higher mortality, it is important to reduce the development 
of CDI in these circumstances.
There have been several studies investigating the relation-
ship between PPIs and the incidence of CDI, even in patients 
without prior history of hospitalization or antibiotic usage.20-22 
The causes are not clear, but loss of the acidic environment of 
the stomach caused by PPI use weakens the defense against 
ingested spores and bacteria, which could be a basis for this as-
sociation.12,17
Recently, two meta-analysis studies evaluated the effective-
ness of PPIs versus H2RAs for preventing UGI bleeding.8,11,18 
Their results were contradictory. Lin et al.8 reported that PPIs 
were not better for preventing UGI bleeding than H2RAs. In 
contrast, Kim et al.11 reported that PPIs were better than H2RAs. 
The American Society of Health-System Pharmacists guidelines 
for SUP do not specify which drug to use.23 In our study, medi-
cation for SUP was chosen based on the physician’s experience 
and preference.
Antibiotic exposure is a well-established risk factor for CDI. 
In the present study, antibiotic use was classified by number 
and type of antibiotics (cephalosporin, fluoroquinolone, peni-
cillin, vancomycin, and carbapenem). However, we found no 
association between antibiotic types and the incidence of SUP-
related CDI. These results can be explained by the fact that most 
of the enrolled patients (834/1,005, 83.0%) received antibiotics 
for a variety of reasons, making it difficult to discern a sig-
nificant effect of antibiotics use. SUP-related CDI group was 
received more number of antibiotics than “no CDI group” (92.1% 
vs 82.6%), although it is not statically significant. Therefore, we 
think these results do not imply that there is no association be-
tween antibiotics use and the development of CDI. Risk factors 
for the development of CDI identified from the previous studies 
were antibiotics use, older age, extended hospital stay and im-
munosuppressive treatment, as well as use of PPIs.10,11,16 How-
ever, there was no association between above risk factors except 
PPIs use and the development of CDI in this study. 
In our study, DM was an independent risk factor for the 
development of SUP-related CDI. In most of previous studies 
published, DM was not a significant risk factor for CDI. Mean-
while, one study examining quinolone-induced CDI showed DM 
as a risk factor for CDI development.24 Considering that obesity 
might be a risk factor for CDI25 and DM is a typical obesity-re-
lated comorbidity, it might be assumed that DM is related to the 
occurrence of CDI as a result of obesity-related dysregulation of 
the immune system, decreased cell-mediated immunity or some 
other mechanism.25-27 On the other hand, in our study, body 
mass index was not a risk factor for the development of SUP-
related CDI. Adjusting such conflicting results, it is suggested to 
be needed further study with large sample size.
In the present study, there are several differences in baseline 
characteristics between the PPI group and the H2RA group 
(Table 2). The PPI group had higher mean age, longer SUP and 
more comorbidities than the H2RA group, whereas the H2RA 
group had longer ICU stay, higher rates of steroid use, mechani-
cal ventilator apply, and mortality, suggesting these differences 
between two groups might affect the results of our study. How-
ever, the multivariate analysis after adjusting confounding fac-
tors such as age, comorbidities, and steroid use, demonstrated 
that PPIs use is an independent risk factor for the development 
of SUP-related CDI.
Our study has several limitations. First, it was retrospective 
and we investigated only part of the period of hospitalization, 
namely from admission to 3 days after discontinuation of SUP. 
And several other medications might have influenced the occur-
rence of CDI. Secondly, we could not determine whether PPIs 
and H2RAs were prescribed for the purpose of SUP in all the 
enrolled patients. We simply included all patients who did not 
receive gastric acid suppressants within 2 months of admission 
and who started these medications in the ICU. And, some of en-
rolled patients could have taken antibiotics, PPI, or H2RA from 
other hospitals before admission to ICU. Thirdly, it was unclear 
what proportion of GI hemorrhage patients were enrolled in 
this study. Fourthly, the severity of comorbidity may be more 
important than whether the patient has the comorbidity or not. 
However, this study did not consider the severities of the comor-
bidities. Fifthly, in the present study, 40 patients were excluded 
due to the prior use of antibiotics before admission. The prior 
use of antibiotics before admission could be a predictive factor 
for CDI occurrence. Because this study was performed in a ret-
rospective manner, it was difficult to accurately investigate the 
history of antibiotics use before admission. Lastly, the PPIs were 
used for a longer period than the H2RAs, which might affect the 
development of CDI. However, there was no difference in the 
total period of SUP between the “SUP-related CDI group” and 
the “no CDI group.” To validate our results, further prospective 
randomized controlled trial with larger sample size is warranted. 
In conclusion, PPI therapy in critically ill patients is associ-
ated with a higher risk of SUP-related CDI than H2RA therapy, 
suggesting that clinicians may consider using H2RAs rather 
than PPIs for SUP in these circumstances.
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